[Asymmetric dimethylarginine--a novel cardiovascular risk factor] - PubMed
[Article in Czech]
Affiliations
- PMID: 16722156
Review
[Asymmetric dimethylarginine--a novel cardiovascular risk factor]
[Article in Czech]
R Siroká et al. Vnitr Lek. 2006 Mar.
Abstract
Understanding metabolism of nitric oxide (NO), signal molecule releasing from endothelial cells and influencing vascular tone, belongs to the most remarkable knowledge of last ten years. NO increases vascular tone, inhibits adhesion of monocytes and leukocytes to the vascular endothelium and reduces atherogenic process. Low NO level is one of pathogenic factors starting cardiovascular diseases. Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of enzyme NO synthase, enzyme catalyzing NO production from arginine. This article gives a brief overview of contemporary state of the relation between ADMA and cardiovascular diseases. Increased ADMA levels are associated with reduced NO synthesis as assessed by impaired endothelium-dependent vasodilatation. In several prospective studies, ADMA evolved as a marker of cardiovascular risk. In the first chapters is described state of the art of biosynthesis, degradation and excretion of ADMA in connection with endothelial dysfunction, coronary artery disease, chronic heart failure, cardiovascular risk in haemodialysis patients, diabetes mellitus, hypertension, lipid metabolism disorders and intensive care unit treatment. Next chapters shortly summarize methods of ADMA detection and their applications. In conclusion clinical relevance of measurement of ADMA levels as a marker of endothelial dysfunction is discussed. Future research tasks of ADMA lead to prospective studies with different types of patients and also healthy population. Moreover ADMA is becoming a goal for pharmacotherapeutic intervention to improve endothelium-dependent vascular function in subjects with high ADMA levels.
Similar articles
-
Böger RH. Böger RH. Vasc Med. 2005 Jul;10 Suppl 1:S19-25. doi: 10.1177/1358836X0501000104. Vasc Med. 2005. PMID: 16444865 Review.
-
Association of asymmetric dimethylarginine and endothelial dysfunction.
Böger RH. Böger RH. Clin Chem Lab Med. 2003 Nov;41(11):1467-72. doi: 10.1515/CCLM.2003.225. Clin Chem Lab Med. 2003. PMID: 14656027 Review.
-
The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor.
Böger RH. Böger RH. Cardiovasc Res. 2003 Oct 1;59(4):824-33. doi: 10.1016/s0008-6363(03)00500-5. Cardiovasc Res. 2003. PMID: 14553822 Review.